Literature DB >> 1375483

Cytotoxicity of 5-aza-2'-deoxycytidine in a mammalian cell system.

S Davidson1, P Crowther, J Radley, D Woodcock.   

Abstract

After the addition of 5-aza-2'-deoxycytidine, a potent inhibitor of DNA methylation and S-phase-specific cytotoxic agent, metaphase chromosomes of Chinese hamster ovary (CHO) cells exhibited a highly decondensed and extended morphology (numerous "fragile sites") at the first mitotic division. However, when a lethal dose of this drug was added in early G1 phase to cells synchronised by mitotic selection, the majority subsequently divided at the same time as an untreated control cell population with few division abnormalities and with few of the more usual types of chromosome aberrations such as gaps, breaks and exchanges. The drug-treated cells also entered and completed the second S-phase without significant delay and it was only at the second mitosis after addition of 5-azadeoxycytidine that cells showed delays in entering mitosis and significant increases in abnormal divisions concomitant with a modest increase in chromosome aberrations. If cells in a tumour behave similarly, the tumour mass would be expected to double before any reduction in tumour burden could be expected to occur.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1375483     DOI: 10.1016/s0959-8049(05)80054-1

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  11 in total

1.  Reprogramming of pig dermal fibroblast into insulin secreting cells by a brief exposure to 5-aza-cytidine.

Authors:  G Pennarossa; S Maffei; M Campagnol; M M Rahman; T A L Brevini; F Gandolfi
Journal:  Stem Cell Rev Rep       Date:  2014-02       Impact factor: 5.739

2.  Replication independent DNA double-strand break retention may prevent genomic instability.

Authors:  Narisorn Kongruttanachok; Chutipa Phuangphairoj; Araya Thongnak; Wanpen Ponyeam; Prakasit Rattanatanyong; Wichai Pornthanakasem; Apiwat Mutirangura
Journal:  Mol Cancer       Date:  2010-03-31       Impact factor: 27.401

3.  2'-Deoxy-N4-[2-(4-nitrophenyl)ethoxycarbonyl]-5-azacytidine: a novel inhibitor of DNA methyltransferase that requires activation by human carboxylesterase 1.

Authors:  Hyang-Min Byun; Si Ho Choi; Peter W Laird; Binh Trinh; Maqbool A Siddiqui; Victor E Marquez; Allen S Yang
Journal:  Cancer Lett       Date:  2008-05-21       Impact factor: 8.679

4.  S-adenosyl-L-homocysteine: a non-cytotoxic hypomethylating agent.

Authors:  S F De Cabo; M J Hazen; M L Molero; J Fernández-Piqueras
Journal:  Experientia       Date:  1994-07-15

Review 5.  DNA hypomethylation in cancer cells.

Authors:  Melanie Ehrlich
Journal:  Epigenomics       Date:  2009-12       Impact factor: 4.778

6.  Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation.

Authors:  R Jüttermann; E Li; R Jaenisch
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

Review 7.  Genome-wide assays that identify and quantify modified cytosines in human disease studies.

Authors:  Netha Ulahannan; John M Greally
Journal:  Epigenetics Chromatin       Date:  2015-01-22       Impact factor: 4.954

8.  The epigenetic modifiers 5-aza-2'-deoxycytidine and trichostatin A influence adipocyte differentiation in human mesenchymal stem cells.

Authors:  J Zych; M A Stimamiglio; A C Senegaglia; P R S Brofman; B Dallagiovanna; S Goldenberg; A Correa
Journal:  Braz J Med Biol Res       Date:  2013-05       Impact factor: 2.590

9.  Inhibition of de novo Methyltransferase 3B is a Potential Therapy for Hepatocellular Carcinoma.

Authors:  Hong Fan; Jian Cheng; Zhu Jiang Zhao
Journal:  Gastroenterology Res       Date:  2008-11-20

10.  An Initial Investigation of an Alternative Model to Study rat Primordial Germ Cell Epigenetic Reprogramming.

Authors:  Isabelle Hernandez Cantão; Renato Borges Tesser; Taiza Stumpp
Journal:  Biol Proced Online       Date:  2017-08-03       Impact factor: 3.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.